Last reviewed · How we verify
NCT06926595: GVHD-PTCy
Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
Phase 2 trial testing Cyclophosphamide (primary intervention for GVHD prophylaxis) in Graft-versus-Host Disease (GVHD) in 41 participants. Currently enrolling.
1 November 2030
Quick facts
| Lead sponsor | Milton S. Hershey Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 9 March 2026 |
| Primary completion | 1 November 2030 |
| Estimated completion | 1 November 2031 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cyclophosphamide (primary intervention for GVHD prophylaxis) — full drug profile →
Conditions studied
- Graft-versus-Host Disease (GVHD) — all drugs for Graft-versus-Host Disease (GVHD) →
- Hematologic Malignancies — all drugs for Hematologic Malignancies →
- Allogeneic Stem Cell Transplantation — all drugs for Allogeneic Stem Cell Transplantation →
Sponsor
Milton S. Hershey Medical Center
Who can join
18 and older, any sex, with Graft-versus-Host Disease (GVHD) or Hematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Phase 2, single-arm, open-label study aims to evaluate the safety and efficacy of low-dose (25 mg/kg) post-transplant cyclophosphamide (PTCy) for prophylaxis of Graft-versus-Host Disease (GVHD) in patients undergoing allogeneic stem cell transplantation following reduced-intensity or non-myeloablative conditioning. The study will focus on matched sibling, matched unrelated, and haploidentical peripheral blood stem cell donors. The primary endpoint is 1-year GVHD-Free Relapse-Free Survival (GRFS). The study seeks to determine if low-dose PTCy offers similar outcomes as higher doses, with potentially reduced toxicity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06926595
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Milton S. Hershey Medical Center trials
Trials by the same sponsor.
- NCT05180552 — The HEALiX: Comparing the Efficacy of the HEALiX Device With Wrist Restraints in a Critical Care Setting · NA · withdrawn
- NCT07461844 — Transdiagnostic Sleep and Circadian Treatment for Autistic Adults · NA · not yet recruiting
- NCT06253858 — Ultrasound (US) Guided External Ventricular Catheter Placement · NA · not yet recruiting
- NCT07225699 — IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING · NA · not yet recruiting
- NCT07461168 — Penn State Emergency Medicine CarES: Care-partner Evaluation and Sourcing in the Emergency Department · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06926595 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Milton S. Hershey Medical Center
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06926595.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing